Evidence map›Paper›PMID 38930952›Full record

ArticleMolecules (Basel, Switzerland)2024

Investigation of the Efficacy of Benzylidene-3-methyl-2-thioxothiazolidin-4-one Analogs with Antioxidant Activities on the Inhibition of Mushroom and Mammal Tyrosinases.

Hye Jin Kim, Hee Jin Jung, Young Eun Kim, Daeun Jeong, Hyeon Seo Park, Hye Soo Park, Dongwan Kang, Yujin Park, Pusoon Chun, Hae Young Chung and 1 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Heterocycles in Medicinal Chemistry II.Molecules (Basel, Switzerland) · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hye Jin KimDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.ORCID 0009-0007-3545-2073
Hee Jin JungDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0001-7212-5572
Young Eun KimDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.
Daeun JeongDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.
Hyeon Seo ParkDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.ORCID 0009-0004-8249-9366
Hye Soo ParkDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.ORCID 0009-0008-5061-7988
Dongwan KangDepartment of Medicinal Chemistry, New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.ORCID 0009-0008-0948-1193
Yujin ParkDepartment of Medicinal Chemistry, New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.ORCID 0009-0006-6438-1780
Pusoon ChunCollege of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae 50834, Gyeongnam, Republic of Korea.ORCID 0000-0002-7349-9880
Hae Young ChungDepartment of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0002-3215-8828
Hyung Ryong MoonDepartment of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0003-1119-7112

Funding

Basic Science Research Program Through the National Research Foundation (NRF) of Korea funded the Ministry of Education NRF-2021R1I1A1A01052284National Research Foundation of Korea (NRF) grant funded by the Korean government (MIST) NRF-2020R1A2C1004198
6 · The paper itself

Abstract

Based on the fact that substances with a β-phenyl-α,β-unsaturated carbonyl (PUSC) motif confer strong tyrosinase inhibitory activity, benzylidene-3-methyl-2-thioxothiazolidin-4-one (BMTTZD) analogs

Indexed as

AgaricalesAntioxidantsEnzyme InhibitorsMelaninsMolecular Docking SimulationMonophenol MonooxygenaseAnimalsBenzylidene CompoundsCell Line, TumorKineticsMelanoma, ExperimentalMicePyronesThiazolidinesAntioxidantsBenzylidene CompoundsEnzyme Inhibitorskojic acidMelaninsMonophenol MonooxygenasePyronesThiazolidinesBMTTZDdocking simulationmelanintyrosinaseβ-phenyl-α,β-unsaturated carbonyl

Identifiers

PMID38930952
PMCPMC11206987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.